REVA Announces Dr. David Muller as Co-Principal Investigator for RESTORE II Clinical Trial

        Print
| Source: REVA Medical, Inc.

SAN DIEGO, Sept. 12, 2012 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) ("REVA" or the "Company") is pleased to announce the appointment of Dr. David Muller, Director, Cardiac Catheterization at St. Vincent's Hospital, Sydney, as co-principal investigator for the Company's upcoming RESTORE II clinical trial, which is expected to begin enrolling patients in the first quarter of 2013. Dr. Alexandre Abizaid of Dante Pazzanese Institute of Cardiology, who successfully led REVA's initial RESTORE pilot study, will continue as a co-principal investigator with Dr. Muller for the RESTORE II trial.

Dr. Muller is a renowned interventional cardiologist and leads the stenting efforts at one of Australia's largest and most prestigious centers.  "I am most pleased to join an excellent group of physician colleagues to evaluate the performance of REVA's unique ReZolve2 drug-eluting bioresorbable scaffold," commented Dr. Muller.  "I am honored to join Dr. Abizaid as Co-PI in overseeing REVA's expanding trial efforts in numerous countries around the world."

Commented Chairman and CEO Robert Stockman, "We are so pleased to add Dr. Muller to the roster of exceptional clinicians who have helped us pioneer the development of our unique product. We have looked forward to Australia's participation as a leading center of clinical trial excellence for REVA and with Dr. Muller at Australia's helm we couldn't be in better hands."

The RESTORE II trial is a multicenter safety and performance study of REVA's ReZolve2 sirolimus-eluting bioresorbable coronary scaffold that will enroll 125 patients at up to 30 clinical centers in Australia, Austria, Brazil, Germany, New Zealand and Poland.  Data gathered from the RESTORE II trial will be used as the basis to support CE mark application of the ReZolve2 scaffold. 

Forward Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management. All statements that are not historical, including those statements that address future operating performance and events or developments that we expect or anticipate will occur in the future, are forward-looking statements. You should not place undue reliance on these forward-looking statements. Although management believes these forward-looking statements are reasonable as and when made, forward-looking statements are subject to a number of risks and uncertainties that may cause our actual results to vary materially from those expressed in the forward-looking statements, including our ability to obtain the regulatory approvals required to market our ReZolve® scaffold, our ability to timely and successfully complete our clinical trials, our ability to protect our intellectual property position, our ability to commercialize our products if and when approved, our ability to develop and commercialize new products, and our estimates regarding our capital requirements and financial performance, including profitability. Other risks and uncertainties that may cause our actual results to vary materially from any forward-looking statements are described in the "Risk Factors" section of our Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (the "SEC") on February 28, 2012, as updated in our Quarterly Report on Form 10-Q filed with the SEC for the periods ended March 31, 2012 and June 30, 2012. We may update our risk factors from time to time in our periodic reports or other current reports filed with the SEC. Any forward-looking statements in this announcement speak only as of the date when made. REVA does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

About REVA

REVA is a development stage medical device company incorporated in Delaware, USA, that is focused on the development and eventual commercialization of its proprietary, bioresorbable stent products. REVA's initial product, the ReZolve® scaffold, which is in a clinical study phase, combines REVA's proprietary stent design with a proprietary polymer that is metabolized and cleared from the body. The ReZolve scaffold is designed to offer full x-ray visibility, clinically relevant sizing and a controlled and safe resorption rate. In addition, by early encapsulation of the stent in the artery tissue coupled with the loss of scaffold structure over time, the ReZolve scaffold may reduce the incidence of late forming blood clots, or thrombosis, a rare but serious problem associated with drug-eluting metal stents currently on the market. REVA will require clinical results and regulatory approval before it can begin selling the ReZolve scaffold. 

The REVA Medical, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8505

United States
Investor and Media Enquiries:
Cheryl Liberatore
Director, Investor Relations and Marketing
REVA Medical, Inc.
+1 858 966-3045

Australia
Investor Enquiries:
Kim Jacobs or Alan Taylor
Inteq Limited
+61 2 9231 3322

Media Enquiries:
Katie Mackenzie or Rebecca Wilson
Buchan Consulting
+61 3 9866 4722